Isotechnika Pharma Inc IPHAF

So what do people think now

[blog]

So what do people think now, there has been some time to watch the webcasts and read presentations. Below is another good news report. An analyst attending the American Transplant Congress in San Francisco, where Isotechnika held a symposium over the weekend, said the results are "very exciting" as current drugs can result in kidney toxicity, hypomagnesemia, and neurological side effects (headache, insomnia), as well as diabetes. He added that the trial's principal investigators told anecdotes of people calling them and asking to be enrolled in the trial after hearing how well it worked from other patients at the hospital. "This is a winner in the making," the analyst said, noting that if Isotechnika's marketing partner, Roche Holding AG (RHHBY), decides to take the program forward, it will have to make a US$70 million milestone payment to Isotechnika. And such a sum would alleviate the company's financial worries for a long time, the analyst said.